---
{"dg-publish":true,"permalink":"/USMLE/Endocrine/Primary hyperaldosteronism/"}
---

# Epidemiology


---
# Etiology
- Most commonly due to the following conditions: 
	- Bilateral idiopathic hyperplasia of the adrenal glands (∼ 60%) 
	- Aldosterone-producing adrenal adenoma or aldosteronoma (∼ 30%)

---
# Pathophysiology
## Autonomous aldosterone secretion and hypertension
- Physiological aldosterone secretion is regulated by the renin-angiotensin-aldosterone system (RAAS) and occurs in response to the detection of low blood pressure in the kidneys.
- ↑ Aldosterone → ↑ open Na<sup>+</sup> channels in principal cells of luminal membrane at the cortical collecting ducts of the kidneys → ↑ Na<sup>+</sup> reabsorption and retention → water retention → hypertension
- <span style="background:rgba(240, 200, 0, 0.2)">Aldosterone escape</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Definition: Evasion of the Na<sup>+</sup>-retaining effects of inappropriately elevated aldosterone levels in primary hyperaldosteronism</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Mechanism: sodium and water retention → volume expansion → secretion of atrial natriuretic peptide (ANP) and pressure natriuresis → compensatory diuresis → “escape” from edema formation and hypernatremia</span>![Pasted image 20250514152226.png](/img/user/appendix/Pasted%20image%2020250514152226.png)
## [[USMLE/Cardiology/Hypokalemia\|Hypokalemia]] and metabolic alkalosis
- ↑ Na<sup>+</sup> reabsorption → electronegative lumen → electrical gradient through open K<sup>+</sup> channels → ↑ K<sup>+</sup> secretion → <span style="background:rgba(240, 200, 0, 0.2)">[[USMLE/Cardiology/Hypokalemia\|hypokalemia]]</span>
- [[USMLE/Cardiology/Hypokalemia\|Hypokalemia]] → metabolic alkalosis via two mechanisms (both of which decrease extracellular H<sup>+</sup>, thereby <span style="background:rgba(240, 200, 0, 0.2)">increasing extracellular pH</span>):
	- <span style="background:rgba(240, 200, 0, 0.2)">Efflux of K<sup>+</sup> from intracellular to extracellular space in exchange for H<sup>+</sup></span>
	- <span style="background:rgba(240, 200, 0, 0.2)">↑ H<sup>+</sup> secretion in the kidney in order to enable ↑ K<sup>+</sup> reabsorption</span>
- [[USMLE/Renal/Diabetes insipidus\|Diabetes insipidus]]: [[USMLE/Cardiology/Hypokalemia\|hypokalemia]] → desensitization of renal tubules to antidiuretic hormone (ADH) → polyuria and polydipsia

---
# Clinical features
- Hypertension
- <span style="background:rgba(240, 200, 0, 0.2)">Features of [[USMLE/Cardiology/Hypokalemia\|hypokalemia]] </span>
	- Fatigue
	- <span style="background:rgba(240, 200, 0, 0.2)">Muscle weakness, cramping</span>
	- [[USMLE/Neurology/Headaches\|Headaches]]
- Absence of significant edema (due to aldosterone escape)
>[!tip] 
>Primary hyperaldosteronism is characterized by [[USMLE/Cardiology/Hypokalemia\|hypokalemia]] and drug-resistant hypertension.

---
# Diagnostics

# Differential diagnostics
### Secondary hyperaldosteronism
- Etiology
	- [[USMLE/Cardiology/Renal artery stenosis\|Renal artery stenosis]] (e.g., due to [[USMLE/Cardiology/Atherosclerosis\|atherosclerosis]], [[USMLE/MSK/Fibromuscular dysplasia\|fibromuscular dysplasia]])
	- <span style="background:rgba(240, 200, 0, 0.2)">Renin-secreting tumor</span>
	- [[USMLE/Renal/Chronic kidney disease\|Chronic kidney disease]]
	- Advanced CHF
	- [[USMLE/MSK/Fibromuscular dysplasia\|Fibromuscular dysplasia]]
	- Liver [[USMLE/GI/Cirrhosis\|cirrhosis]]
	- [[USMLE/Pharmacology/Diuretics\|Diuretics]]
	- Laxative abuse
- Diagnostics: ↑ PAC (Plasma aldosterone concentration) and ↑ PRA (Plasma renin activity)

---
# Treatment
- Unilateral disease or adrenal carcinoma: surgery preferred
- Bilateral disease: medical management preferred
	- Bilateral adrenalectomy has a low success rate for curing hypertension and also leaves the patient dependent on lifelong glucocorticoid replacement; for this reason, medical management is recommended for bilateral disease.
## Medical management
- First-line: aldosterone receptor antagonists
	- <span style="background:rgba(240, 200, 0, 0.2)">Spironolactone (preferred)</span>
	- Eplerenone
		- In contrast to spironolactone, <span style="background:rgba(240, 200, 0, 0.2)">eplerenone does not block [[USMLE/Reproductive/Androgen and estrogen synthesis\|androgen]] or progesterone receptors, which decreases certain side effects</span> (e.g., gynecomastia and decreased libido); <span style="background:rgba(240, 200, 0, 0.2)">however, eplerenone is only half as potent</span> at blocking the mineralocorticoid receptor and is less effective at lowering blood pressure.

---
